Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Dermatophyte infection Clinical criteria: Patient must have failed to respond to topical treatment. Population criteria: Patient must be an Aboriginal or a Torres Strait Islander person.
Onychomycosis Clinical criteria: The condition must be proximal or extensive (greater than 80% nail involvement), AND Patient must have failed to respond to topical treatment, AND The condition must be due to dermatophyte infection proven by microscopy and confirmed by an Approved Pathology Provider; OR The condition must be due to dermatophyte infection proven by culture and confirmed by an Approved Pathology Provider. The date of the pathology report must be provided at the time of application and must not be more than 12 months old
Fungal or yeast infection Clinical criteria: Population criteria: Patient must be an Aboriginal or a Torres Strait Islander person.
“Terbinafine interferes specifically with fungal sterol biosynthesis at an early step. This leads to a deficiency in ergosterol and to an intracellular accumulation of squalene, resulting in fungal cell death. Terbinafine acts by inhibition of squalene epoxidase in the fungal cell membrane.”
“The elimination half-life is 17 hours.”
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“In vitro and in vivo studies showed negligible potential for interaction with the drugs that are metabolised via the CYP450 system except those with CYP2D6-mediated metabolism. Terbinafine inhibits the CYP2D6-mediated metabolism.”